[PDF][PDF] Meningioma: the unusual growth in a transsexual patient after estrogen-progesterone therapy
H Borghei-Razavi, V Fragoza-Padilla, G Hargus… - SOJ Neurol, 2014 - academia.edu
H Borghei-Razavi, V Fragoza-Padilla, G Hargus, S Bakhti, U Schick
SOJ Neurol, 2014•academia.eduIntroduction The frequency of meningioma is nearly twice as high in females as in males [1].
This difference in incidence is partly explained by molecular and immunehistochemical
studies' indicating that meningioma is sensitive to hormones. Approximately 70% of
meningiomas express progesterone receptors and 30% express estrogen receptors [2-4]. It
has also been observed that meningioma cells tend to proliferate when exposed to estrogen
and progesterone [4]. Although cross-sex hormone treatment is an important component of …
This difference in incidence is partly explained by molecular and immunehistochemical
studies' indicating that meningioma is sensitive to hormones. Approximately 70% of
meningiomas express progesterone receptors and 30% express estrogen receptors [2-4]. It
has also been observed that meningioma cells tend to proliferate when exposed to estrogen
and progesterone [4]. Although cross-sex hormone treatment is an important component of …
Introduction The frequency of meningioma is nearly twice as high in females as in males [1]. This difference in incidence is partly explained by molecular and immunehistochemical studies’ indicating that meningioma is sensitive to hormones. Approximately 70% of meningiomas express progesterone receptors and 30% express estrogen receptors [2-4]. It has also been observed that meningioma cells tend to proliferate when exposed to estrogen and progesterone [4].
Although cross-sex hormone treatment is an important component of medical treatment of transsexual patients, several adverse effects are associated with its use, such as osteoporosis, cardiovascular disease, hormone-dependent tumors (eg, lactotroph adenomas), breast and prostate carcinomas. Specifically, research on Hormone Replacement Therapy (HRT) indicates that the risk of developing meningioma may be higher in transsexual patients due to relatively high doses of sex hormones [5, 6]
academia.edu